Linked Life Data

21519323

Source:http://linkedlifedata.com/resource/pubmed/id/21519323

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-4-26
pubmed:abstractText
There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1? (Interleukin 1 ?) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0391-1977
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
147-56
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes?
pubmed:affiliation
Unit of Endocrinology and Metabolism, Hull York Medical School, Hull, UK. thozhukat.sathyapalan@hyms.ac.uk
pubmed:publicationType
Journal Article, Review